title: Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer.
abstract: Recently, many therapeutic agents for prostate cancer have been approved that target the androgen receptor and/or the prostate tumor microenvironment. Each of these therapies has modestly increased patient survival. A better understanding of when in the course of prostate cancer progression specific therapies should be applied, and of what biomarkers would indicate when resistance arises, would almost certainly improve survival due to these therapies. Thus, applying the armamentarium of therapeutic agents in the right sequences in the right combination at the right time is a major goal in prostate cancer treatment. For this to occur, an understanding of prostate cancer evolution during progression is required. In this review, we discuss the current understanding of prostate cancer progression, but challenge the prevailing view by proposing a new model of prostate cancer progression, with the goal of improving biologic classification and treatment strategies. We use this model to discuss how integrating clinical and basic understanding of prostate cancer will lead to better implementation of molecularly targeted therapeutics and improve patient survival.
authors.affiliation: Departments of 1Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. clogothe@mdanderson.org
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: Logothetis
authors.forename: Gary E
authors.initials: GE
authors.lastname: Gallick
authors.forename: Sankar N
authors.initials: SN
authors.lastname: Maity
authors.forename: Jeri
authors.initials: J
authors.lastname: Kim
authors.forename: Ana
authors.initials: A
authors.lastname: Aparicio
authors.forename: Eleni
authors.initials: E
authors.lastname: Efstathiou
authors.forename: Sue-Hwa
authors.initials: SH
authors.lastname: Lin
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis*; D018450:Disease Progression; D055808:Drug Discovery; D006801:Humans; D008297:Male; D058990:Molecular Targeted Therapy; D011471:Prostatic Neoplasms / Q000145:classification / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology*; D011944:Receptors, Androgen / Q000235:genetics / Q000378:metabolism*; D016896:Treatment Outcome; D059016:Tumor Microenvironment
chemical_list: C410798:AR protein, human; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D011944:Receptors, Androgen